Previous 10 | Next 10 |
Gainers: Longeveron (LGVN) +62%. Clovis Oncology (CLVS) +61%. Icosavax (ICVX) +26%. Integrated Media Technology (IMTE) +28%. SAB Biotherapeutics (SABS) +21%. Local Bounti (LOCL) +21%. CPS Technologies (CPSH) +18%. Vector Group (VGR) +17%. Nano-X Imaging (NNOX) +16%. Vertex Energy (VTNR) +16%....
Clovis Oncology, Inc. (NASDAQ: CLVS) reported positive data from the monotherapy arm of ATHENA (GOG 3020/ENGOT-ov45) trial (ATHENA-MONO) demonstrating that Rubraca as maintenance treatment successfully achieved its primary endpoint of significantly improving investigator-...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Advanced Micro Devices (NASDAQ: AMD ) stock is slipping on Thursday as investors react to a new rating from Barclays analyst Blayne Curtis. Source: Joseph GTK / Shutterstock.com The Barclays analyst hit AMD st...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clovis Oncology (NASDAQ: CLVS ) stock is in the news Thursday as shares rocket higher thanks to positive data from a recent clinical trial. Source: CI Photos / Shutterstock.com That data comes from the company...
Gainers: Clovis Oncology CLVS +68%. Longeveron LGVN +36%. Icosavax (ICVX) +27%. Creative Medical Technology (CELZ) +25%. Nano-X Imaging NNOX +22%. Losers: Clarus Therapeutics CRXT -27%. Acutus Medical AFIB -18%. Vyant Bio VYNT -15%. Phree...
Buying Penny Stocks Today? Here’s What You Need to Know With another day of trading penny stocks and blue chips here, there is a lot for investors to know. Recently, we’ve seen a bullish streak with 4 days of gains in the market. However, in the last day or so, this sentim...
Clovis Oncology (CLVS) +45% meets key goal for ovarian cancer therapy in late-stage trial. Longeveron (LGVN) +36% publishes peer reviewed study of phase 1 trial results of Lomecel-B for alzheimer’s disease in alzheimer’s & dementia: the journal of the alzheime...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! Get ready for another busy day of trading with the biggest pre-market stock movers for Thursday! Source: f11photo/Shutterstock.com Earnings reports, cancer data, financing, and more have stocks...
Clovis Oncology (NASDAQ:CLVS) have added ~52% in the pre-market Thursday after the commercial-stage biotech company announced that its ovarian cancer therapy Rubraca (Rucaparib) achieved primary endpoint as maintenance treatment in a late-stage trial involving women with ovarian cancer. ...
ATHENA study evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: HRD-positive and all patients randomized (ITT) Median PFS of 20.2 months for Rubraca vs 9...
News, Short Squeeze, Breakout and More Instantly...
Receives Commitment for up to $75 Million in Debtor-in-Possession Financing Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., E...